

SAFETY DATA SHEETS

This SDS packet was issued with item:

078057148

The safety data sheets (SDS) in this packet apply to the individual products listed below. Please refer to invoice for specific item number(s).

078391483 078926029 078926030

The safety data sheets (SDS) in this packet apply to one or more components included in the items listed below. Items listed below may require one or more SDS. Please refer to invoice for specific item number(s).

078057155 078856641 078856658



MATERIAL SAFETY DATA SHEET

Revision date: 14-Mar-2007

Version: 1.1

Page 1 of 6

1. IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND THE COMPANY/UNDERTAKING

Pfizer Animal Health
Pfizer Inc
235 East 42nd Street
New York, NY 10017
Poison Control Center Phone: 1-866-531-8896
Technical Services Phone: 1-800-366-5288

Pfizer Ltd,
Kent
CT13 9NJ
United Kingdom
+00 44 (0)1304 616161

Emergency telephone number:
CHEMTREC (24 hours): 1-800-424-9300

Emergency telephone number:
ChemSafe (24 hours): +44 (0)208 762 8322

Material Name: Pyrantel Pamoate Tablets

Trade Name: PYR-A-PAM; NEMEX; CANEX
Chemical Family: Mixture
Intended Use: Veterinary product used as anti-worm agent (anthelmintic)

2. COMPOSITION/INFORMATION ON INGREDIENTS

Hazardous

Ingredient	CAS Number	EU EINECS List	%
Pyrantel pamoate	22204-24-6	244-837-1	78
Sodium lauryl sulfate	151-21-3	205-788-1	*
Magnesium Stearate	557-04-0	209-150-3	*
Corn Starch	9005-25-8	232-679-6	*

Ingredient	CAS Number	EU EINECS List	%
FD&C yellow No.6 aluminum lake	15790-07-5	239-888-1	*
Alginic acid	9005-32-7	232-680-1	*

Additional Information: * Proprietary
Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety.

3. HAZARDS IDENTIFICATION

Appearance: Round, convex orange tablet

Statement of Hazard: Non-hazardous in accordance with international standards for workplace safety.

Additional Hazard Information:

Short Term: An Occupational Exposure Limit has been established for one or more of the ingredients (see Section 8).
Long Term: Repeat-dose studies in animals have shown a potential to cause adverse effects on gastrointestinal system, liver.

Known Clinical Effects: Ingestion of this material may cause effects similar to those seen in clinical use including nausea, vomiting, abdominal cramps, anorexia, diarrhea, and constipation. Occasional, transient changes reported in liver function tests, but no liver damage seen.

EU Indication of danger: Not classified

MATERIAL SAFETY DATA SHEET

Material Name: Pyrantel Pamoate Tablets
Revision date: 14-Mar-2007

Page 2 of 6
Version: 1.1

Note: This document has been prepared in accordance with standards for workplace safety, which require the inclusion of all known hazards of the active substance or its intermediates regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

4. FIRST AID MEASURES

Eye Contact: Immediately flush eyes with water for at least 15 minutes. If irritation occurs or persists, get medical attention.

Skin Contact: Wash skin with soap and water. Remove contaminated clothing and shoes. If irritation occurs or persists, get medical attention.

Ingestion: Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.

Inhalation: Remove to fresh air and keep patient at rest. Seek medical attention immediately.

5. FIRE FIGHTING MEASURES

Extinguishing Media: Use carbon dioxide, dry chemical, or water spray.

Hazardous Combustion Products: Emits toxic fumes of carbon monoxide, carbon dioxide, nitrogen oxides, sulfur oxides and other sulfur-containing compounds.

Fire Fighting Procedures: Wear approved positive pressure, self-contained breathing apparatus and full protective turn out gear. Evacuate area and fight fire from a safe distance.

Fire / Explosion Hazards: Not applicable

6. ACCIDENTAL RELEASE MEASURES

Health and Safety Precautions: Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

Measures for Cleaning / Collecting: Contain the source of spill if it is safe to do so. Collect spilled material by a method that controls dust generation. A damp cloth or a filtered vacuum should be used to clean spills of dry solids. Clean spill area thoroughly.

Measures for Environmental Protections: Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

Additional Consideration for Large Spills: Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Clean up operations should only be undertaken by trained personnel.

7. HANDLING AND STORAGE

General Handling: If tablets or capsules are crushed and/or broken, avoid breathing dust and avoid contact with eyes, skin, and clothing.

Storage Conditions: Store as directed by product packaging.

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Pyrantel pamoate

MATERIAL SAFETY DATA SHEET

Material Name: Pyrantel Pamoate Tablets
Revision date: 14-Mar-2007

Page 3 of 6
Version: 1.1

Pfizer OEL TWA-8 Hr: 0.3 mg/m³

Sodium lauryl sulfate

Pfizer OEL TWA-8 Hr: 0.3 mg/m³
Pfizer STEL 0.75 mg/m³

Magnesium Stearate

ACGIH Threshold Limit Value (TWA) = 10 mg/m³ TWA except stearates of toxic metals
Australia TWA = 10 mg/m³ TWA

Corn Starch

OSHA - Final PELs - TWAs: = 15 mg/m³ TWA total
= 5 mg/m³ TWA
ACGIH Threshold Limit Value (TWA) = 10 mg/m³ TWA
Australia TWA = 10 mg/m³ TWA
The exposure limit(s) listed for solid components are only relevant if dust may be generated.

Engineering Controls:

Engineering controls should be used as the primary means to control exposures. Local and general ventilation should be used as necessary, when handling this material in bulk.

Personal Protective Equipment:

Hands: Not required for the normal use of this product. Wear protective gloves when working with large quantities.
Eyes: Not required under normal conditions of use. Wear safety glasses or goggles if eye contact is possible.
Skin: Not required for the normal use of this product. Wear protective clothing when working with large quantities.
Respiratory protection: Not required for the normal use of this product. If the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL.

9. PHYSICAL AND CHEMICAL PROPERTIES:

Physical State:	Tablets	Color:	Orange
Molecular Formula:	Mixture	Molecular Weight:	Mixture

10. STABILITY AND REACTIVITY

Stability: Stable under normal conditions of use.
Conditions to Avoid: None known
Incompatible Materials: As a precautionary measure, keep away from strong oxidizers.

11. TOXICOLOGICAL INFORMATION

General Information: The information included in this section describes the potential hazards of the individual ingredients.

Acute Toxicity: (Species, Route, End Point, Dose)

Pyrantel pamoate

Mouse Oral LD50 > 24 g/kg

MATERIAL SAFETY DATA SHEET

Material Name: Pyrantel Pamoate Tablets
Revision date: 14-Mar-2007

Page 4 of 6
Version: 1.1

Rat Oral LD50 > 24 g/kg
Mouse Intraperitoneal LD50 620 mg/kg
Rat Intraperitoneal LD50 535 mg/kg

Alginic acid

Rat Oral LD50 > 5 g/kg

Sodium lauryl sulfate

Rat Oral LD50 1288 mg/kg

Acute Toxicity Comments:

A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable at the highest dose used in the test.

Irritation / Sensitization: (Study Type, Species, Severity)

Sodium lauryl sulfate

Eye Irritation Rabbit Severe

Skin Irritation Rabbit Severe

Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

Pyrantel pamoate

1 Month(s)	Rat	Oral	500 mg/kg/day	NOAEL	None identified
1 Month(s)	Dog	Oral	50 mg/kg/day	LOAEL	Gastrointestinal system, Liver
13 Week(s)	Rat	Oral	300 mg/kg/day	NOAEL	None identified
13 Week(s)	Dog	Oral	100 mg/kg/day	NOAEL	Gastrointestinal system, Liver

Magnesium Stearate

13 Week(s) Rat Oral 1092 g/kg LOAEL Liver

Reproduction & Developmental Toxicity: (Study Type, Species, Route, Dose, End Point, Effect(s))

Pyrantel pamoate

Reproductive & Fertility	Rat	Oral	250 mg/kg	NOAEL	No effects at maximum dose
Prenatal & Postnatal Development	Rat	Oral	250 mg/kg	NOAEL	No effects at maximum dose
Embryo / Fetal Development	Rat	Oral	250 mg/kg	NOAEL	Not Teratogenic
Embryo / Fetal Development	Rabbit	Oral	250 mg/kg	NOAEL	Not Teratogenic

Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

Pyrantel pamoate

Bacterial Mutagenicity (Ames) *Salmonella* Negative

Carcinogen Status:

None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA.

12. ECOLOGICAL INFORMATION

Environmental Overview:

The environmental characteristics of this material have not been fully evaluated. Releases to the environment should be avoided.

MATERIAL SAFETY DATA SHEET

Material Name: Pyrantel Pamoate Tablets
Revision date: 14-Mar-2007

Page 5 of 6
Version: 1.1

13. DISPOSAL CONSIDERATIONS

Disposal Procedures: Dispose of waste in accordance with all applicable laws and regulations.

14. TRANSPORT INFORMATION

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

15. REGULATORY INFORMATION

EU Indication of danger: Not classified

OSHA Label:

Non-hazardous in accordance with international standards for workplace safety.

Canada - WHMIS: Classifications

WHMIS hazard class:

None required

This product has been classified in accordance with the hazard criteria of the CPR and the MSDS contains all of the information required by the CPR.

Pyrantel pamoate

Australia (AICS):	Present
EU EINECS List	244-837-1

Sodium lauryl sulfate

Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS List	205-788-1

FD&C yellow No.6 aluminum lake

Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS List	239-888-1

Magnesium Stearate

Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS List	209-150-3

Corn Starch

Inventory - United States TSCA - Sect. 8(b)	XU
Australia (AICS):	Present
EU EINECS List	232-679-6

MATERIAL SAFETY DATA SHEET

Material Name: Pyrantel Pamoate Tablets
Revision date: 14-Mar-2007

Page 6 of 6
Version: 1.1

Alginic acid

Inventory - United States TSCA - Sect. 8(b)

XU

Australia (AICS):

Present

EU EINECS List

232-680-1

16. OTHER INFORMATION

Prepared by:

Toxicology and Hazard Communication
Pfizer Global Environment, Health, and Safety

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without a warranty of any kind, expressed or implied.

End of Safety Data Sheet

SAFETY DATA SHEET



Revision date: 03-Jun-2014

Version: 2.1

Page 1 of 8

1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND THE COMPANY/UNDERTAKING

Product Identifier

Material Name: Pyrantel Pamoate Tablets

Trade Name: PYR-A-PAM; NEMEX; CANEX
Chemical Family: Mixture

Relevant Identified Uses of the Substance or Mixture and Uses Advised Against

Intended Use: Veterinary product used as anti-worm agent (anthelmintic)

Details of the Supplier of the Safety Data Sheet

Zoetis Inc.
100 Campus Drive, P.O. Box 651
Florham Park, New Jersey 07932 (USA)
Rocky Mountain Poison Control Center Phone: 1-866-531-8896
Product Support/Technical Services Phone: 1-800-366-5288

Zoetis Belgium S.A.
Mercuriusstraat 20
1930 Zaventem
Belgium

Emergency telephone number:
CHEMTREC (24 hours): 1-800-424-9300
Contact E-Mail: VMIPSrecords@zoetis.com

Emergency telephone number:
International CHEMTREC (24 hours): +1-703-527-3887

2. HAZARDS IDENTIFICATION

Appearance: Round, convex orange tablet

Classification of the Substance or Mixture

GHS - Classification Not classified as hazardous

EU Classification:

EU Indication of danger: Not classified

Label Elements

Signal Word: Not Classified
Hazard Statements: Non-hazardous in accordance with international standards for workplace safety.

Other Hazards

Short Term: May be harmful if swallowed. May produce allergic reactions following skin contact.
Long Term: Repeat-dose studies in animals have shown a potential to cause adverse effects on gastrointestinal system, liver.
Known Clinical Effects: Ingestion of this material may cause effects similar to those seen in clinical use including nausea, vomiting, abdominal cramps, anorexia, diarrhea, and constipation. Occasional, transient changes reported in liver function tests, but no liver damage seen.
Australian Hazard Classification (NOHSC): Non-Hazardous Substance. Non-Dangerous Goods.

SAFETY DATA SHEET

Material Name: Pyrantel Pamoate Tablets
Revision date: 03-Jun-2014

Page 2 of 8
Version: 2.1

Note: This document has been prepared in accordance with standards for workplace safety, which requires the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warning included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

3. COMPOSITION/INFORMATION ON INGREDIENTS

Hazardous

Ingredient	CAS Number	EU EINECS/ELINCS List	EU Classification	GHS Classification	%
Pyrantel pamoate	22204-24-6	244-837-1	Not Listed	Not Listed	78
Sodium Lauryl Sulfate	151-21-3	205-788-1	Xn R22 T R24	Acute Tox 4 (H302) Acute Tox 3 (H311)	<1
Magnesium Stearate	557-04-0	209-150-3	Not Listed	Not Listed	*
Corn Starch	9005-25-8	232-679-6	Not Listed	Not Listed	*

Ingredient	CAS Number	EU EINECS/ELINCS List	EU Classification	GHS Classification	%
FD&C yellow No.6 aluminum lake	15790-07-5	239-888-1	Not Listed	Not Listed	*
Alginic acid	9005-32-7	232-680-1	Not Listed	Not Listed	*

Additional Information: * Proprietary
Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety.

For the full text of the R phrases and CLP/GHS abbreviations mentioned in this Section, see Section 16

4. FIRST AID MEASURES

Description of First Aid Measures

Eye Contact: Immediately flush eyes with water for at least 15 minutes. If irritation occurs or persists, get medical attention.

Skin Contact: Wash skin with soap and water. Remove contaminated clothing and shoes. If irritation occurs or persists, get medical attention.

Ingestion: Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.

Inhalation: Remove to fresh air and keep patient at rest. Seek medical attention immediately.

Most Important Symptoms and Effects, Both Acute and Delayed

Symptoms and Effects of No data available

Exposure:

Medical Conditions None known

Aggravated by Exposure:

Indication of the Immediate Medical Attention and Special Treatment Needed

Notes to Physician: None

SAFETY DATA SHEET

Material Name: Pyrantel Pamoate Tablets
Revision date: 03-Jun-2014

Page 3 of 8
Version: 2.1

5. FIRE-FIGHTING MEASURES

Extinguishing Media: Extinguish fires with CO₂, extinguishing powder, foam, or water.

Special Hazards Arising from the Substance or Mixture

Hazardous Combustion Products: Formation of toxic gases is possible during heating or fire.

Fire / Explosion Hazards: Fine particles (such as dust and mists) may fuel fires/explosions.

Advice for Fire-Fighters

Wear approved positive pressure, self-contained breathing apparatus and full protective turn out gear. Dike and collect water used to fight fire.

6. ACCIDENTAL RELEASE MEASURES

Personal Precautions, Protective Equipment and Emergency Procedures

Avoid dust formation. Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

Environmental Precautions

Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

Methods and Material for Containment and Cleaning Up

Measures for Cleaning / Collecting: Contain the source of spill if it is safe to do so. Collect spilled material by a method that controls dust generation. A damp cloth or a filtered vacuum should be used to clean spills of dry solids. Clean spill area thoroughly.

Additional Consideration for Large Spills: Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Clean up operations should only be undertaken by trained personnel.

7. HANDLING AND STORAGE

Precautions for Safe Handling

When handling, use proper personal protective equipment as specified in Section 8. If tablets or capsules are crushed and/or broken, avoid breathing dust and avoid contact with eyes, skin, and clothing. Wash thoroughly after handling. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.

Conditions for Safe Storage, Including any Incompatibilities

Storage Conditions: Store as directed by product packaging.

Specific end use(s): No data available

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Control Parameters

Refer to available public information for specific member state Occupational Exposure Limits.

Pyrantel pamoate

Zoetis OEL TWA 8-hr 300µg/m³

Sodium Lauryl Sulfate

Zoetis OEL TWA 8-hr 300µg/m³

SAFETY DATA SHEET

Material Name: Pyrantel Pamoate Tablets
Revision date: 03-Jun-2014

Page 4 of 8
Version: 2.1

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Magnesium Stearate

ACGIH Threshold Limit Value (TWA)	10 mg/m ³
Lithuania OEL - TWA	5 mg/m ³
Sweden OEL - TWAs	5 mg/m ³

Corn Starch

ACGIH Threshold Limit Value (TWA)	10 mg/m ³
Australia TWA	10 mg/m ³
Belgium OEL - TWA	10 mg/m ³
Bulgaria OEL - TWA	10.0 mg/m ³
Czech Republic OEL - TWA	4.0 mg/m ³
Greece OEL - TWA	10 mg/m ³
	5 mg/m ³
Ireland OEL - TWAs	10 mg/m ³
	4 mg/m ³
OSHA - Final PELs - TWAs:	15 mg/m ³
Portugal OEL - TWA	10 mg/m ³
Slovakia OEL - TWA	4 mg/m ³
Spain OEL - TWA	10 mg/m ³
Switzerland OEL - TWAs	3 mg/m ³

Exposure Controls

Engineering Controls:	Engineering controls should be used as the primary means to control exposures. General room ventilation is adequate unless the process generates dust, mist or fumes.
Personal Protective Equipment:	Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE).
Hands:	Wear impervious gloves if skin contact is possible.
Eyes:	Safety glasses or goggles
Skin:	Use protective clothing (uniforms, lab coats, disposable coveralls, etc.) in both production and laboratory areas.
Respiratory protection:	If the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL.

9. PHYSICAL AND CHEMICAL PROPERTIES

Physical State:	Tablets	Color:	Orange
Odor:	No data available.	Odor Threshold:	No data available.
Molecular Formula:	Mixture	Molecular Weight:	Mixture
Solvent Solubility:	No data available		
Water Solubility:	No data available		
pH:	No data available.		
Melting/Freezing Point (°C):	No data available		
Boiling Point (°C):	No data available.		
Partition Coefficient: (Method, pH, Endpoint, Value)			
	No data available		
Decomposition Temperature (°C):	No data available.		
Evaporation Rate (Gram/s):	No data available		
Vapor Pressure (kPa):	No data available		
Vapor Density (g/ml):	No data available		

SAFETY DATA SHEET

Material Name: Pyrantel Pamoate Tablets
Revision date: 03-Jun-2014

Page 5 of 8
Version: 2.1

Relative Density: No data available
Viscosity: No data available

Flammability:

Autoignition Temperature (Solid) (°C):	No data available
Flammability (Solids):	No data available
Flash Point (Liquid) (°C):	No data available
Upper Explosive Limits (Liquid) (% by Vol.):	No data available
Lower Explosive Limits (Liquid) (% by Vol.):	No data available

10. STABILITY AND REACTIVITY

Reactivity: No data available
Chemical Stability: Stable under normal conditions of use.
Possibility of Hazardous Reactions
Oxidizing Properties: No data available
Conditions to Avoid: Fine particles (such as dust and mists) may fuel fires/explosions.
Incompatible Materials: As a precautionary measure, keep away from strong oxidizers
Hazardous Decomposition Products: No data available

11. TOXICOLOGICAL INFORMATION

Information on Toxicological Effects

General Information: Toxicological properties of the formulation have not been fully investigated. The information included in this section describes the potential hazards of the individual ingredients.

Acute Toxicity: (Species, Route, End Point, Dose)

Pyrantel pamoate

Mouse	Oral	LD50	> 24 g/kg
Rat	Oral	LD50	> 24g/kg
Mouse	Intraperitoneal	LD50	620mg/kg
Rat	Intraperitoneal	LD50	535mg/kg

Alginate acid

Rat	Oral	LD50	> 5 g/kg
-----	------	------	----------

Sodium Lauryl Sulfate

Rat	Oral	LD50	977 mg/kg
Rabbit	Dermal	LD50	580mg/kg
Rat	Inhalation	LC50	> 3900mg/m ³ 1 h

Acute Toxicity Comments: A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable at the highest dose used in the test.

Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

Pyrantel pamoate

1 Month(s)	Rat	Oral	500 mg/kg/day	NOAEL	None identified
1 Month(s)	Dog	Oral	50 mg/kg/day	LOAEL	Gastrointestinal system, Liver
13 Week(s)	Rat	Oral	300 mg/kg/day	NOAEL	None identified
13 Week(s)	Dog	Oral	100 mg/kg/day	NOAEL	Gastrointestinal system, Liver

SAFETY DATA SHEET

Material Name: Pyrantel Pamoate Tablets
Revision date: 03-Jun-2014

Page 6 of 8
Version: 2.1

11. TOXICOLOGICAL INFORMATION

Magnesium Stearate

13 Week(s) Rat Oral 1092 g/kg LOEL Liver

Reproduction & Developmental Toxicity: (Study Type, Species, Route, Dose, End Point, Effect(s))

Pyrantel pamoate

Reproductive & Fertility	Rat	Oral	250 mg/kg	NOAEL	No effects at maximum dose
Prenatal & Postnatal Development	Rat	Oral	250 mg/kg	NOAEL	No effects at maximum dose
Embryo / Fetal Development	Rat	Oral	250 mg/kg	NOAEL	Not Teratogenic
Embryo / Fetal Development	Rabbit	Oral	250 mg/kg	NOAEL	Not Teratogenic

Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

Pyrantel pamoate

Bacterial Mutagenicity (Ames) *Salmonella* Negative

Carcinogen Status: None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA.

12. ECOLOGICAL INFORMATION

Environmental Overview:	The environmental characteristics of this material have not been fully evaluated. Releases to the environment should be avoided.
Toxicity:	No data available
Persistence and Degradability:	No data available
Bio-accumulative Potential:	No data available
Mobility in Soil:	No data available

13. DISPOSAL CONSIDERATIONS

Waste Treatment Methods: Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

14. TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

PZ00502

SAFETY DATA SHEET

Material Name: Pyrantel Pamoate Tablets
Revision date: 03-Jun-2014

Page 7 of 8
Version: 2.1

15. REGULATORY INFORMATION

Safety, Health and Environmental Regulations/Legislation Specific for the Substance or Mixture

Canada - WHMIS: Classifications

WHMIS hazard class:

None required

This product has been classified in accordance with the hazard criteria of the CPR and the MSDS contains all of the information required by the CPR.

Pyrantel pamoate

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Australia (AICS):	Present
EU EINECS/ELINCS List	244-837-1

Sodium Lauryl Sulfate

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
Standard for the Uniform Scheduling for Drugs and Poisons:	Schedule 6
EU EINECS/ELINCS List	205-788-1

FD&C yellow No.6 aluminum lake

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	239-888-1

Magnesium Stearate

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	209-150-3

Corn Starch

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present

SAFETY DATA SHEET

Material Name: Pyrantel Pamoate Tablets
Revision date: 03-Jun-2014

Page 8 of 8
Version: 2.1

15. REGULATORY INFORMATION

REACH - Annex IV - Exemptions from the obligations of Register:	Present
EU EINECS/ELINCS List	232-679-6

Alginic acid

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	232-680-1

16. OTHER INFORMATION

Text of R phrases and GHS Classification abbreviations mentioned in Section 3

H302 - Harmful if swallowed
H311 - Toxic in contact with skin

T - Toxic
Xn - Harmful

R22 - Harmful if swallowed.
R24 - Toxic in contact with skin.

Data Sources:

The data contained in this MSDS may have been gathered from confidential internal sources, raw material suppliers, or from the published literature.

Reasons for Revision:

Updated Section 1 - Identification of the Substance/Preparation and the Company/Undertaking.
Updated Section 2 - Hazard Identification. Updated Section 3 - Composition / Information on Ingredients. Updated Section 5 - Fire Fighting Measures. Updated Section 7 - Handling and Storage. Updated Section 8 - Exposure Controls / Personal Protection.

Prepared by:

Toxicology and Hazard Communication
Zoetis Global Risk Management

Zoetis Inc. believes that the information contained in this Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.

End of Safety Data Sheet

SAFETY DATA SHEET



Revision date: 03-Jun-2014

Version: 2.1

Page 1 of 8

1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND THE COMPANY/UNDERTAKING

Product Identifier

Material Name: Pyrantel Pamoate Tablets

Trade Name: PYR-A-PAM; NEMEX; CANEX
Chemical Family: Mixture

Relevant Identified Uses of the Substance or Mixture and Uses Advised Against

Intended Use: Veterinary product used as anti-worm agent (anthelmintic)

Details of the Supplier of the Safety Data Sheet

Zoetis Inc.
100 Campus Drive, P.O. Box 651
Florham Park, New Jersey 07932 (USA)
Rocky Mountain Poison Control Center Phone: 1-866-531-8896
Product Support/Technical Services Phone: 1-800-366-5288

Zoetis Belgium S.A.
Mercuriusstraat 20
1930 Zaventem
Belgium

Emergency telephone number:
CHEMTREC (24 hours): 1-800-424-9300
Contact E-Mail: VMIPSrecords@zoetis.com

Emergency telephone number:
International CHEMTREC (24 hours): +1-703-527-3887

2. HAZARDS IDENTIFICATION

Appearance: Round, convex orange tablet

Classification of the Substance or Mixture

GHS - Classification Not classified as hazardous

EU Classification:

EU Indication of danger: Not classified

Label Elements

Signal Word: Not Classified
Hazard Statements: Non-hazardous in accordance with international standards for workplace safety.

Other Hazards

Short Term: May be harmful if swallowed. May produce allergic reactions following skin contact.
Long Term: Repeat-dose studies in animals have shown a potential to cause adverse effects on gastrointestinal system, liver.
Known Clinical Effects: Ingestion of this material may cause effects similar to those seen in clinical use including nausea, vomiting, abdominal cramps, anorexia, diarrhea, and constipation. Occasional, transient changes reported in liver function tests, but no liver damage seen.
Australian Hazard Classification (NOHSC): Non-Hazardous Substance. Non-Dangerous Goods.

SAFETY DATA SHEET

Material Name: Pyrantel Pamoate Tablets
Revision date: 03-Jun-2014

Page 2 of 8
Version: 2.1

Note: This document has been prepared in accordance with standards for workplace safety, which requires the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warning included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

3. COMPOSITION/INFORMATION ON INGREDIENTS

Hazardous

Ingredient	CAS Number	EU EINECS/ELINCS List	EU Classification	GHS Classification	%
Pyrantel pamoate	22204-24-6	244-837-1	Not Listed	Not Listed	78
Sodium Lauryl Sulfate	151-21-3	205-788-1	Xn R22 T R24	Acute Tox 4 (H302) Acute Tox 3 (H311)	<1
Magnesium Stearate	557-04-0	209-150-3	Not Listed	Not Listed	*
Corn Starch	9005-25-8	232-679-6	Not Listed	Not Listed	*

Ingredient	CAS Number	EU EINECS/ELINCS List	EU Classification	GHS Classification	%
FD&C yellow No.6 aluminum lake	15790-07-5	239-888-1	Not Listed	Not Listed	*
Alginic acid	9005-32-7	232-680-1	Not Listed	Not Listed	*

Additional Information: * Proprietary
Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety.

For the full text of the R phrases and CLP/GHS abbreviations mentioned in this Section, see Section 16

4. FIRST AID MEASURES

Description of First Aid Measures

Eye Contact: Immediately flush eyes with water for at least 15 minutes. If irritation occurs or persists, get medical attention.

Skin Contact: Wash skin with soap and water. Remove contaminated clothing and shoes. If irritation occurs or persists, get medical attention.

Ingestion: Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.

Inhalation: Remove to fresh air and keep patient at rest. Seek medical attention immediately.

Most Important Symptoms and Effects, Both Acute and Delayed

Symptoms and Effects of No data available

Exposure:

Medical Conditions None known

Aggravated by Exposure:

Indication of the Immediate Medical Attention and Special Treatment Needed

Notes to Physician: None

SAFETY DATA SHEET

Material Name: Pyrantel Pamoate Tablets
Revision date: 03-Jun-2014

Page 3 of 8
Version: 2.1

5. FIRE-FIGHTING MEASURES

Extinguishing Media: Extinguish fires with CO₂, extinguishing powder, foam, or water.

Special Hazards Arising from the Substance or Mixture

Hazardous Combustion Products: Formation of toxic gases is possible during heating or fire.

Fire / Explosion Hazards: Fine particles (such as dust and mists) may fuel fires/explosions.

Advice for Fire-Fighters

Wear approved positive pressure, self-contained breathing apparatus and full protective turn out gear. Dike and collect water used to fight fire.

6. ACCIDENTAL RELEASE MEASURES

Personal Precautions, Protective Equipment and Emergency Procedures

Avoid dust formation. Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

Environmental Precautions

Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

Methods and Material for Containment and Cleaning Up

Measures for Cleaning / Collecting: Contain the source of spill if it is safe to do so. Collect spilled material by a method that controls dust generation. A damp cloth or a filtered vacuum should be used to clean spills of dry solids. Clean spill area thoroughly.

Additional Consideration for Large Spills: Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Clean up operations should only be undertaken by trained personnel.

7. HANDLING AND STORAGE

Precautions for Safe Handling

When handling, use proper personal protective equipment as specified in Section 8. If tablets or capsules are crushed and/or broken, avoid breathing dust and avoid contact with eyes, skin, and clothing. Wash thoroughly after handling. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.

Conditions for Safe Storage, Including any Incompatibilities

Storage Conditions: Store as directed by product packaging.

Specific end use(s): No data available

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Control Parameters

Refer to available public information for specific member state Occupational Exposure Limits.

Pyrantel pamoate

Zoetis OEL TWA 8-hr 300µg/m³

Sodium Lauryl Sulfate

Zoetis OEL TWA 8-hr 300µg/m³

SAFETY DATA SHEET

Material Name: Pyrantel Pamoate Tablets
Revision date: 03-Jun-2014

Page 4 of 8
Version: 2.1

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Magnesium Stearate

ACGIH Threshold Limit Value (TWA)	10 mg/m ³
Lithuania OEL - TWA	5 mg/m ³
Sweden OEL - TWAs	5 mg/m ³

Corn Starch

ACGIH Threshold Limit Value (TWA)	10 mg/m ³
Australia TWA	10 mg/m ³
Belgium OEL - TWA	10 mg/m ³
Bulgaria OEL - TWA	10.0 mg/m ³
Czech Republic OEL - TWA	4.0 mg/m ³
Greece OEL - TWA	10 mg/m ³
	5 mg/m ³
Ireland OEL - TWAs	10 mg/m ³
	4 mg/m ³
OSHA - Final PELs - TWAs:	15 mg/m ³
Portugal OEL - TWA	10 mg/m ³
Slovakia OEL - TWA	4 mg/m ³
Spain OEL - TWA	10 mg/m ³
Switzerland OEL - TWAs	3 mg/m ³

Exposure Controls

Engineering Controls:	Engineering controls should be used as the primary means to control exposures. General room ventilation is adequate unless the process generates dust, mist or fumes.
Personal Protective Equipment:	Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE).
Hands:	Wear impervious gloves if skin contact is possible.
Eyes:	Safety glasses or goggles
Skin:	Use protective clothing (uniforms, lab coats, disposable coveralls, etc.) in both production and laboratory areas.
Respiratory protection:	If the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL.

9. PHYSICAL AND CHEMICAL PROPERTIES

Physical State:	Tablets	Color:	Orange
Odor:	No data available.	Odor Threshold:	No data available.
Molecular Formula:	Mixture	Molecular Weight:	Mixture
Solvent Solubility:	No data available		
Water Solubility:	No data available		
pH:	No data available.		
Melting/Freezing Point (°C):	No data available		
Boiling Point (°C):	No data available.		
Partition Coefficient: (Method, pH, Endpoint, Value)			
	No data available		
Decomposition Temperature (°C):	No data available.		
Evaporation Rate (Gram/s):	No data available		
Vapor Pressure (kPa):	No data available		
Vapor Density (g/ml):	No data available		

SAFETY DATA SHEET

Material Name: Pyrantel Pamoate Tablets
Revision date: 03-Jun-2014

Page 5 of 8
Version: 2.1

Relative Density: No data available
Viscosity: No data available

Flammability:

Autoignition Temperature (Solid) (°C):	No data available
Flammability (Solids):	No data available
Flash Point (Liquid) (°C):	No data available
Upper Explosive Limits (Liquid) (% by Vol.):	No data available
Lower Explosive Limits (Liquid) (% by Vol.):	No data available

10. STABILITY AND REACTIVITY

Reactivity: No data available
Chemical Stability: Stable under normal conditions of use.
Possibility of Hazardous Reactions
Oxidizing Properties: No data available
Conditions to Avoid: Fine particles (such as dust and mists) may fuel fires/explosions.
Incompatible Materials: As a precautionary measure, keep away from strong oxidizers
Hazardous Decomposition Products: No data available

11. TOXICOLOGICAL INFORMATION

Information on Toxicological Effects

General Information: Toxicological properties of the formulation have not been fully investigated. The information included in this section describes the potential hazards of the individual ingredients.

Acute Toxicity: (Species, Route, End Point, Dose)

Pyrantel pamoate

Mouse	Oral	LD50	> 24 g/kg
Rat	Oral	LD50	> 24g/kg
Mouse	Intraperitoneal	LD50	620mg/kg
Rat	Intraperitoneal	LD50	535mg/kg

Alginate acid

Rat	Oral	LD50	> 5 g/kg
-----	------	------	----------

Sodium Lauryl Sulfate

Rat	Oral	LD50	977 mg/kg
Rabbit	Dermal	LD50	580mg/kg
Rat	Inhalation	LC50	> 3900mg/m ³ 1 h

Acute Toxicity Comments: A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable at the highest dose used in the test.

Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

Pyrantel pamoate

1 Month(s)	Rat	Oral	500 mg/kg/day	NOAEL	None identified
1 Month(s)	Dog	Oral	50 mg/kg/day	LOAEL	Gastrointestinal system, Liver
13 Week(s)	Rat	Oral	300 mg/kg/day	NOAEL	None identified
13 Week(s)	Dog	Oral	100 mg/kg/day	NOAEL	Gastrointestinal system, Liver

SAFETY DATA SHEET

Material Name: Pyrantel Pamoate Tablets
Revision date: 03-Jun-2014

Page 6 of 8
Version: 2.1

11. TOXICOLOGICAL INFORMATION

Magnesium Stearate

13 Week(s) Rat Oral 1092 g/kg LOEL Liver

Reproduction & Developmental Toxicity: (Study Type, Species, Route, Dose, End Point, Effect(s))

Pyrantel pamoate

Reproductive & Fertility	Rat	Oral	250 mg/kg	NOEL	No effects at maximum dose
Prenatal & Postnatal Development	Rat	Oral	250 mg/kg	NOEL	No effects at maximum dose
Embryo / Fetal Development	Rat	Oral	250 mg/kg	NOEL	Not Teratogenic
Embryo / Fetal Development	Rabbit	Oral	250 mg/kg	NOEL	Not Teratogenic

Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

Pyrantel pamoate

Bacterial Mutagenicity (Ames) *Salmonella* Negative

Carcinogen Status: None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA.

12. ECOLOGICAL INFORMATION

Environmental Overview:	The environmental characteristics of this material have not been fully evaluated. Releases to the environment should be avoided.
Toxicity:	No data available
Persistence and Degradability:	No data available
Bio-accumulative Potential:	No data available
Mobility in Soil:	No data available

13. DISPOSAL CONSIDERATIONS

Waste Treatment Methods: Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

14. TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

PZ00502

SAFETY DATA SHEET

Material Name: Pyrantel Pamoate Tablets
Revision date: 03-Jun-2014

Page 7 of 8
Version: 2.1

15. REGULATORY INFORMATION

Safety, Health and Environmental Regulations/Legislation Specific for the Substance or Mixture

Canada - WHMIS: Classifications

WHMIS hazard class:

None required

This product has been classified in accordance with the hazard criteria of the CPR and the MSDS contains all of the information required by the CPR.

Pyrantel pamoate

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Australia (AICS):	Present
EU EINECS/ELINCS List	244-837-1

Sodium Lauryl Sulfate

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
Standard for the Uniform Scheduling for Drugs and Poisons:	Schedule 6
EU EINECS/ELINCS List	205-788-1

FD&C yellow No.6 aluminum lake

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	239-888-1

Magnesium Stearate

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	209-150-3

Corn Starch

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present

SAFETY DATA SHEET

Material Name: Pyrantel Pamoate Tablets
Revision date: 03-Jun-2014

Page 8 of 8
Version: 2.1

15. REGULATORY INFORMATION

REACH - Annex IV - Exemptions from the obligations of Register:	Present
EU EINECS/ELINCS List	232-679-6

Alginic acid

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	232-680-1

16. OTHER INFORMATION

Text of R phrases and GHS Classification abbreviations mentioned in Section 3

H302 - Harmful if swallowed
H311 - Toxic in contact with skin

T - Toxic
Xn - Harmful

R22 - Harmful if swallowed.
R24 - Toxic in contact with skin.

Data Sources:

The data contained in this MSDS may have been gathered from confidential internal sources, raw material suppliers, or from the published literature.

Reasons for Revision:

Updated Section 1 - Identification of the Substance/Preparation and the Company/Undertaking.
Updated Section 2 - Hazard Identification. Updated Section 3 - Composition / Information on Ingredients. Updated Section 5 - Fire Fighting Measures. Updated Section 7 - Handling and Storage. Updated Section 8 - Exposure Controls / Personal Protection.

Prepared by:

Toxicology and Hazard Communication
Zoetis Global Risk Management

Zoetis Inc. believes that the information contained in this Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.

End of Safety Data Sheet

SAFETY DATA SHEET



Revision date: 29-May-2015

Version: 4.4

Page 1 of 9

1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND THE COMPANY/UNDERTAKING

Product Identifier

Material Name: Pyrantel pamoate oral suspension

Trade Name: Nemex, Banminth, NEMEX-2 SUSPENSION, RFD LIQUID WORMER
Synonyms: BANMINTH/NEMEX (PYRANTEL) SUSPENSION
Chemical Family: Tetrahydropyrimidine

Relevant Identified Uses of the Substance or Mixture and Uses Advised Against

Intended Use: Veterinary product used as anti-worm agent (anthelmintic)
Restrictions on Use: Not for human use

Details of the Supplier of the Safety Data Sheet

Zoetis Inc.
100 Campus Drive, P.O. Box 651
Florham Park, New Jersey 07932 (USA)
Rocky Mountain Poison and Drug Center Phone: 1-866-531-8896
Product Support/Technical Services Phone: 1-800-366-5288

Zoetis Belgium S.A.
Mercuriusstraat 20
1930 Zaventem
Belgium

Emergency telephone number:
CHEMTREC (24 hours): 1-800-424-9300
Contact E-Mail: VMIPSrecords@zoetis.com

Emergency telephone number:
International CHEMTREC (24 hours): +1-703-527-3887

2. HAZARDS IDENTIFICATION

Appearance: Yellow suspension
Classification of the Substance or Mixture
GHS - Classification Not classified as hazardous

EU Classification:
EU Indication of danger: Not classified

Label Elements

Signal Word: Not Classified
Hazard Statements: Not classified in accordance with international standards for workplace safety.

Other Hazards

Short Term: May cause mild eye irritation. (based on components) .
Long Term: May cause effects on gastrointestinal system, liver through prolonged or repeated exposure.
Known Clinical Effects: Ingestion of this material may cause effects similar to those seen in clinical use including nausea, vomiting, abdominal cramps, anorexia, diarrhea, and constipation. Occasional, transient changes reported in liver function tests, but no liver damage seen.
Australian Hazard Classification (NOHSC): Non-Hazardous Substance. Non-Dangerous Goods.

SAFETY DATA SHEET

Material Name: Pyrantel pamoate oral suspension
Revision date: 29-May-2015

Page 2 of 9
Version: 4.4

Note: This document has been prepared in accordance with standards for workplace safety, which requires the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warning included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

3. COMPOSITION/INFORMATION ON INGREDIENTS

Hazardous

Ingredient	CAS Number	EU EINECS/ELINCS List	EU Classification	GHS Classification	%
Pyrantel pamoate	22204-24-6	244-837-1	Not Listed	Not Listed	<= 2.27
Magnesium aluminum silicate	1327-43-1	215-478-8	Not Listed	Not Listed	1
Glycerin, USP	56-81-5	200-289-5	Not Listed	Not Listed	1

Ingredient	CAS Number	EU EINECS/ELINCS List	EU Classification	GHS Classification	%
Sorbitol	6706-59-8	Not Listed	Not Listed	Not Listed	*
Lecithin	8002-43-5	232-307-2	Not Listed	Not Listed	*
Sodium benzoate	532-32-1	208-534-8	Not Listed	Not Listed	*
Polysorbate 80	9005-65-6	Not Listed	Not Listed	Not Listed	*
Water, purified	7732-18-5	231-791-2	Not Listed	Not Listed	*

Additional Information: * Proprietary
Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety. In accordance with 29 CFR 1910.1200, the exact percentage composition of this mixture has been withheld as a trade secret.

4. FIRST AID MEASURES

Description of First Aid Measures

Eye Contact: Flush with water while holding eyelids open for at least 15 minutes. Seek medical attention immediately.

Skin Contact: Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek medical attention.

Ingestion: Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.

Inhalation: Remove to fresh air and keep patient at rest. Seek medical attention immediately.

Most Important Symptoms and Effects, Both Acute and Delayed

Symptoms and Effects of Exposure: For information on potential signs and symptoms of exposure, See Section 2 - Hazards Identification and/or Section 11 - Toxicological Information.
Medical Conditions Aggravated by Exposure: None known

Indication of the Immediate Medical Attention and Special Treatment Needed

Notes to Physician: None

SAFETY DATA SHEET

Material Name: Pyrantel pamoate oral suspension
Revision date: 29-May-2015

Page 3 of 9
Version: 4.4

5. FIRE-FIGHTING MEASURES

Extinguishing Media: Use carbon dioxide, dry chemical, or water spray.

Special Hazards Arising from the Substance or Mixture

Hazardous Combustion Products: Formation of toxic gases is possible during heating or fire.

Fire / Explosion Hazards: Fine particles (such as dust and mists) may fuel fires/explosions.

Advice for Fire-Fighters

During all fire fighting activities, wear appropriate protective equipment, including self-contained breathing apparatus.

6. ACCIDENTAL RELEASE MEASURES

Personal Precautions, Protective Equipment and Emergency Procedures

Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

Environmental Precautions

Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

Methods and Material for Containment and Cleaning Up

Measures for Cleaning / Collecting: Contain the source of spill if it is safe to do so. Collect spill with absorbent material. Clean spill area thoroughly.

Additional Consideration for Large Spills: Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Clean up operations should only be undertaken by trained personnel.

7. HANDLING AND STORAGE

Precautions for Safe Handling

When handling, use appropriate personal protective equipment (see Section 8). Avoid contact with eyes, skin and clothing. Avoid breathing vapor or mist. Wash thoroughly after handling. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.

Conditions for Safe Storage, Including any Incompatibilities

Storage Conditions: Store as directed by product packaging.

Storage Temperature: Store at or below 30°C (86°F).

Specific end use(s): No data available

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Control Parameters

Refer to available public information for specific member state Occupational Exposure Limits.

Pyrantel pamoate

Zoetis OEL TWA 8-hr 300µg/m³

Glycerin, USP

Australia TWA 10 mg/m³

Belgium OEL - TWA 10 mg/m³

Czech Republic OEL - TWA 10 mg/m³

SAFETY DATA SHEET

Material Name: Pyrantel pamoate oral suspension
Revision date: 29-May-2015

Page 4 of 9
Version: 4.4

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Estonia OEL - TWA	10 mg/m ³
Finland OEL - TWA	20 mg/m ³
France OEL - TWA	10 mg/m ³
Germany (DFG) - MAK	50 mg/m ³
Greece OEL - TWA	10 mg/m ³
Ireland OEL - TWAs	10 mg/m ³
OSHA - Final PELs - TWAs:	15 mg/m ³
Poland OEL - TWA	10 mg/m ³
Portugal OEL - TWA	10 mg/m ³
Spain OEL - TWA	10 mg/m ³
Switzerland OEL - TWAs	50 mg/m ³

Exposure Controls

Engineering Controls:	Engineering controls should be used as the primary means to control exposures. Keep airborne contamination levels below the exposure limits listed above in this section. General room ventilation is adequate unless the process generates dust, mist or fumes.
Personal Protective Equipment:	Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE).
Hands:	Impervious gloves are recommended if skin contact with drug product is possible and for bulk processing operations.
Eyes:	Wear safety glasses or goggles if eye contact is possible.
Skin:	Impervious protective clothing is recommended if skin contact with drug product is possible and for bulk processing operations.
Respiratory protection:	If the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL.

9. PHYSICAL AND CHEMICAL PROPERTIES

Physical State:	Suspension	Color:	Yellow
Odor:	No data available.	Odor Threshold:	No data available.
Molecular Formula:	Mixture	Molecular Weight:	Mixture
Solvent Solubility:	No data available		
Water Solubility:	No data available		
pH:	4.5-6.0		
Melting/Freezing Point (°C):	No data available		
Boiling Point (°C):	No data available.		
Partition Coefficient: (Method, pH, Endpoint, Value)	No data available		
Decomposition Temperature (°C):	No data available.		
Evaporation Rate (Gram/s):	No data available		
Vapor Pressure (kPa):	No data available		
Vapor Density (g/ml):	No data available		
Relative Density:	No data available		
Viscosity:	No data available		
Flammability:			
Autoignition Temperature (Solid) (°C):	No data available		
Flammability (Solids):	No data available		
Flash Point (Liquid) (°C):	No data available		
Upper Explosive Limits (Liquid) (% by Vol.):	No data available		
Lower Explosive Limits (Liquid) (% by Vol.):	No data available		

SAFETY DATA SHEET

Material Name: Pyrantel pamoate oral suspension
Revision date: 29-May-2015

Page 5 of 9
Version: 4.4

Polymerization: Will not occur

10. STABILITY AND REACTIVITY

Reactivity: No data available
Chemical Stability: Stable under normal conditions of use.
Possibility of Hazardous Reactions
Oxidizing Properties: None
Conditions to Avoid: Fine particles (such as dust and mists) may fuel fires/explosions.
Incompatible Materials: As a precautionary measure, keep away from strong oxidizers
Hazardous Decomposition Products: No data available

11. TOXICOLOGICAL INFORMATION

Information on Toxicological Effects

General Information: Toxicological properties of the formulation have not been investigated. The information in this section describes the potential hazards of the individual ingredients and the formulation.
Routes of exposure: eye contact , skin contact

Acute Toxicity: (Species, Route, End Point, Dose)

Sodium benzoate

Rat Oral LD50 4,070 mg/kg
Mouse Oral LD50 1600mg/kg

Polysorbate 80

Rat Oral LD50 25 g/kg

Glycerin, USP

Mouse Oral LD50 4090 mg/kg
Rat Oral LD50 12.6 g/kg
Rabbit Dermal LD50 > 10 g/kg
Rat Inhalation LC50 1hr > 570 mg/m³
Rat Dermal LD 50 > 21.9 g/kg

Pyrantel pamoate

Mouse Oral LD50 > 24 g/kg
Rat Oral LD50 > 24g/kg
Mouse Intraperitoneal LD50 620mg/kg
Rat Intraperitoneal LD50 535mg/kg

Lecithin

Rat Oral LD50 > 8 ml/kg

Acute Toxicity Comments: A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable at the highest dose used in the test.

Irritation / Sensitization: (Study Type, Species, Severity)

SAFETY DATA SHEET

Material Name: Pyrantel pamoate oral suspension
Revision date: 29-May-2015

Page 6 of 9
Version: 4.4

11. TOXICOLOGICAL INFORMATION

Glycerin, USP

Eye Irritation Rabbit Mild

Irritation / Sensitization Comments: May cause mild eye irritation.

Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

Sodium benzoate

10 Day(s)	Rat	Oral	27370 mg/kg	LOAEL	Liver, Blood
10 Day(s)	Mouse	Oral	45 g/kg	LOAEL	Liver, Kidney, Blood, Ureter, Bladder

Pyrantel pamoate

1 Month(s)	Rat	Oral	500 mg/kg/day	NOAEL	None identified
1 Month(s)	Dog	Oral	50 mg/kg/day	LOAEL	Gastrointestinal system, Liver
13 Week(s)	Rat	Oral	300 mg/kg/day	NOAEL	None identified
13 Week(s)	Dog	Oral	100 mg/kg/day	NOAEL	Gastrointestinal system, Liver

Reproduction & Development Toxicity: (Duration, Species, Route, Dose, End Point, Effect(s))

Sodium benzoate

Embryo / Fetal Development	Rat	Oral	44 g/kg	LOEL	Developmental toxicity,
----------------------------	-----	------	---------	------	-------------------------

Pyrantel pamoate

Reproductive & Fertility	Rat	Oral	250 mg/kg	NOAEL	No effects at maximum dose
Prenatal & Postnatal Development	Rat	Oral	250 mg/kg	NOAEL	No effects at maximum dose
Embryo / Fetal Development	Rat	Oral	250 mg/kg	NOAEL	Not Teratogenic
Embryo / Fetal Development	Rabbit	Oral	250 mg/kg	NOAEL	Not Teratogenic

Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

Pyrantel pamoate

Bacterial Mutagenicity (Ames)	<i>Salmonella</i>	Negative
-------------------------------	-------------------	----------

Carcinogen Status: None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA.

SAFETY DATA SHEET

Material Name: Pyrantel pamoate oral suspension
Revision date: 29-May-2015

Page 7 of 9
Version: 4.4

12. ECOLOGICAL INFORMATION

Environmental Overview: Environmental properties of the formulation have not been investigated. The following information is available for the individual ingredients. Releases to the environment should be avoided.

Toxicity:

Aquatic Toxicity: (Species, Method, End Point, Duration, Result)

Glycerin, USP

<i>Oncorhynchus mykiss</i> (Rainbow Trout)	LD50	96 Hours	50 mg/L
<i>Daphnia magna</i> (Water Flea)	EC50	24 Hours	>500 mg/L

Aquatic Toxicity Comments: A greater than symbol (>) indicates that aquatic toxicity was not observed at the maximum dose tested.

Persistence and Degradability: No data available

Bio-accumulative Potential: No data available

Mobility in Soil: No data available

13. DISPOSAL CONSIDERATIONS

Waste Treatment Methods: Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

14. TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

15. REGULATORY INFORMATION

Safety, Health and Environmental Regulations/Legislation Specific for the Substance or Mixture

Canada - WHMIS: Classifications

SAFETY DATA SHEET

Material Name: Pyrantel pamoate oral suspension
Revision date: 29-May-2015

Page 8 of 9
Version: 4.4

15. REGULATORY INFORMATION

WHMIS hazard class:

Non-controlled

This product has been classified in accordance with the hazard criteria of the CPR and the SDS contains all of the information required by the CPR.

Sorbitol

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
EU EINECS/ELINCS List	Not Listed

Pyrantel pamoate

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Australia (AICS):	Present
EU EINECS/ELINCS List	244-837-1

Magnesium aluminum silicate

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	215-478-8

Glycerin, USP

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
REACH - Annex V - Exemptions from the obligations of Register:	Present if not chemically modified, except they meet the criteria for classification as dangerous according to Directive 67/548/EEC, except those only classified as flammable [R10], as a skin irritant [R38] or as an eye irritant [R36], except they are persistent, bioaccumulative, and toxic or very persistent and very bioaccumulative in accordance with the criteria set out in Annex XIII, except they were identified in accordance with Article 59[1] at least two years previously as substances giving rise to an equivalent level of concern
EU EINECS/ELINCS List	200-289-5

Lecithin

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
REACH - Annex IV - Exemptions from the obligations of Register:	Present
EU EINECS/ELINCS List	232-307-2

Sodium benzoate

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present

SAFETY DATA SHEET

Material Name: Pyrantel pamoate oral suspension
Revision date: 29-May-2015

Page 9 of 9
Version: 4.4

15. REGULATORY INFORMATION

Australia (AICS):	Present
EU EINECS/ELINCS List	208-534-8

Polysorbate 80

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	Not Listed

Water, purified

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
REACH - Annex IV - Exemptions from the obligations of Register:	Present
EU EINECS/ELINCS List	231-791-2

16. OTHER INFORMATION

Data Sources: The data contained in this SDS may have been gathered from confidential internal sources, raw material suppliers, or from the published literature.

Reasons for Revision: Updated Section 1 - Identification of the Substance/Preparation and the Company/Undertaking. Updated Section 2 - Hazard Identification. Updated Section 3 - Composition / Information on Ingredients. Updated Section 11 - Toxicology Information.

Prepared by: Toxicology and Hazard Communication
Zoetis Global Risk Management

Zoetis Inc. believes that the information contained in this Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.

End of Safety Data Sheet